This edition of the Life Science, Health & Wellness TechVision Opportunity Engine (TOE) comprises 26 recent technology innovations across the biopharmaceutical and biomarker platforms for research and clinical applications across the global healthcare industry. The research captures key innovation aspects such as technology readiness levels, market potential, funding, disruptive potential, mega trend impact, and regional adoption scenarios to evaluate the innovation index for each technology profile. A summary of the innovation index has also been provided in a visual radar format.
The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.
The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- ATGC Biotech
- Abacus Diagnostica Oy
- Abionic SA
- Aelix Therapeutics
- Akero Therapeutics
- Akouos
- Allogene Therapeutics
- Aura Biotechnologies
- Aviana Molecular Technologies LLC
- BluSense Diagnostic ApS
- Co-Diagnostics Inc.
- Cue Health Inc.
- Cure.Fit
- Eyestem
- GammaDelta Therapeutics
- Gossamer Bio
- HOOKIPA Pharma Inc.
- Lung Therapeutics
- Magnolia Neurosciences Corporation
- Mitra Biotech
- Ontera Inc.
- Protochips
- Quell Therapeutics
- SAW Diagnostics Limited
- SeLux Diagnostics Inc.
- SpringWorks Therapeutics
